Protalix BioTherapeutics, Inc.
PLX
$1.98
$0.021.02%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 432.79% | -333.72% | 1,335.98% | 104.53% | -155.73% |
| Total Depreciation and Amortization | 4.39% | 4.03% | 3.33% | 4.05% | 3.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -44.13% | 102.51% | -40.72% | 1,976.36% | -90.98% |
| Change in Net Operating Assets | -56.06% | 180.94% | -3.44% | -274.95% | 46.62% |
| Cash from Operations | 984.98% | 154.39% | 28.68% | -3.46% | -226.74% |
| Capital Expenditure | -88.83% | 19.08% | -15.55% | -40.85% | 28.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 802.96% | -11,716.67% | 14.29% | -16.67% | 99.96% |
| Cash from Investing | 479.77% | -120.63% | -15.07% | -40.38% | 97.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.74% | -- | -100.00% | -19.15% | 39.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.74% | -- | -100.00% | -19.15% | 39.99% |
| Foreign Exchange rate Adjustments | -148.39% | -158.33% | -400.00% | 150.00% | -114.81% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,448.02% | 124.32% | -171.79% | -417.55% | 96.05% |